Exicure (XCUR) Competitors $7.95 -0.91 (-10.27%) Closing price 04:00 PM EasternExtended Trading$7.80 -0.15 (-1.82%) As of 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XCUR vs. DMAC, IMAB, TLSA, ACOG, KYTX, RAPT, DERM, ACRS, BDTX, and BIOAShould you be buying Exicure stock or one of its competitors? The main competitors of Exicure include DiaMedica Therapeutics (DMAC), I-Mab (IMAB), Tiziana Life Sciences (TLSA), Alpha Cognition (ACOG), Kyverna Therapeutics (KYTX), Rapt Therapeutics (RAPT), Journey Medical (DERM), Aclaris Therapeutics (ACRS), Black Diamond Therapeutics (BDTX), and BioAge Labs (BIOA). These companies are all part of the "pharmaceutical products" industry. Exicure vs. Its Competitors DiaMedica Therapeutics I-Mab Tiziana Life Sciences Alpha Cognition Kyverna Therapeutics Rapt Therapeutics Journey Medical Aclaris Therapeutics Black Diamond Therapeutics BioAge Labs Exicure (NASDAQ:XCUR) and DiaMedica Therapeutics (NASDAQ:DMAC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability. Do institutionals & insiders believe in XCUR or DMAC? 42.8% of Exicure shares are held by institutional investors. Comparatively, 10.1% of DiaMedica Therapeutics shares are held by institutional investors. 8.4% of Exicure shares are held by insiders. Comparatively, 7.3% of DiaMedica Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media prefer XCUR or DMAC? In the previous week, DiaMedica Therapeutics had 10 more articles in the media than Exicure. MarketBeat recorded 11 mentions for DiaMedica Therapeutics and 1 mentions for Exicure. DiaMedica Therapeutics' average media sentiment score of 0.57 beat Exicure's score of 0.00 indicating that DiaMedica Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exicure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral DiaMedica Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is XCUR or DMAC more profitable? DiaMedica Therapeutics' return on equity of -61.35% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets ExicureN/A -219.60% -82.03% DiaMedica Therapeutics N/A -61.35%-55.53% Which has stronger earnings and valuation, XCUR or DMAC? Exicure has higher revenue and earnings than DiaMedica Therapeutics. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Exicure, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioExicure$500K100.49-$9.70M-$3.82-2.08DiaMedica TherapeuticsN/AN/A-$24.44M-$0.64-7.19 Do analysts recommend XCUR or DMAC? DiaMedica Therapeutics has a consensus price target of $10.75, indicating a potential upside of 133.70%. Given DiaMedica Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe DiaMedica Therapeutics is more favorable than Exicure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, XCUR or DMAC? Exicure has a beta of 3.57, indicating that its stock price is 257% more volatile than the S&P 500. Comparatively, DiaMedica Therapeutics has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500. SummaryDiaMedica Therapeutics beats Exicure on 8 of the 14 factors compared between the two stocks. Get Exicure News Delivered to You Automatically Sign up to receive the latest news and ratings for XCUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XCUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XCUR vs. The Competition Export to ExcelMetricExicureMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$50.24M$2.96B$5.57B$9.41BDividend YieldN/A2.47%4.00%4.03%P/E Ratio-2.0820.5328.3219.89Price / Sales100.49318.06445.96196.39Price / CashN/A40.8024.9928.17Price / Book7.107.808.325.73Net Income-$9.70M-$55.10M$3.24B$258.18M7 Day Performance16.06%6.40%4.20%3.92%1 Month Performance6.43%16.84%10.16%14.31%1 Year Performance1,490.64%3.12%34.69%17.29% Exicure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XCURExicure0.89 of 5 stars$7.95-10.3%N/A+1,555.8%$50.24M$500K-2.0850DMACDiaMedica Therapeutics1.1969 of 5 stars$4.04+0.6%$8.00+98.3%+39.7%$171.52MN/A-6.2520News CoveragePositive NewsIMABI-Mab2.8757 of 5 stars$2.10-1.9%$6.00+185.7%+48.3%$171.49M$3.89M0.00380Analyst DowngradeTLSATiziana Life Sciences1.3854 of 5 stars$1.46-1.7%N/A+90.6%$170.02MN/A0.008News CoverageACOGAlpha Cognition1.1099 of 5 stars$10.53flat$20.00+89.9%N/A$168.69M$2.93M-8.77N/APositive NewsKYTXKyverna Therapeutics1.3953 of 5 stars$3.87-12.0%$18.50+378.0%-61.3%$168.34M$7.03M-1.1596Positive NewsRAPTRapt Therapeutics4.0883 of 5 stars$10.22+17.2%$19.80+93.7%-55.5%$166.99M$1.53M-0.5380Gap UpHigh Trading VolumeDERMJourney Medical1.6179 of 5 stars$7.21-2.7%$9.50+31.8%+31.7%$166.90M$56.13M-18.3790Positive NewsACRSAclaris Therapeutics1.6805 of 5 stars$1.53-3.5%$8.71+471.4%+24.2%$165.13M$18.72M-1.10100BDTXBlack Diamond Therapeutics2.5115 of 5 stars$2.88-2.2%$12.80+345.2%-45.2%$162.90MN/A47.7590BIOABioAge LabsN/A$4.52-2.4%N/AN/A$162.04MN/A0.00N/A Related Companies and Tools Related Companies DiaMedica Therapeutics Alternatives I-Mab Alternatives Tiziana Life Sciences Alternatives Alpha Cognition Alternatives Kyverna Therapeutics Alternatives Rapt Therapeutics Alternatives Journey Medical Alternatives Aclaris Therapeutics Alternatives Black Diamond Therapeutics Alternatives BioAge Labs Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XCUR) was last updated on 7/22/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exicure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exicure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
